Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Payers Must Brace For Coming Wave Of Cell And Gene Therapies

Oct 14 2019

• By Mandy Jackson

Amazing, perfect wave - Image

Related Content

Spark's Luxturna Approval Ushers In A New Gene Therapy Era

Dec 19 2017

Industry Communications With Payors: US FDA Okays Info On Investigational Drugs

Jan 19 2017

Early Engagement On Outcomes-Based Deals Helps Unlock EU Access To Kymriah

Sep 12 2019

The First US Gene Therapy Maker Innovates On Pricing And Reimbursement

Jan 03 2018

Progress Being Made With Cell And Gene Therapy Market Access, But Challenges Remain

Oct 09 2019

Novartis Prepares for UK Luxturna Rollout After Rapid NICE OK

Sep 08 2019

Novartis Beats CAR-T Competitors To The Pricing Punch With Kymriah Approval

Aug 31 2017

Related Companies

Enzyvant Therapeutics, Inc.

Roivant Sciences Ltd.

Spark Therapeutics, Inc.

Novartis AG

Additional Topics

Gene Therapy Reimbursement Pricing Strategies Market Access Regenerative Medicine Rare Diseases Strategy Commercial BioPharmaceutical

More from Gene Therapies

More from Advanced Therapies

Twitter feed RSS feed RSS feed

About UsOpens in new window
Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us
Customer Service
Subscribe
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window